鞍上脑膜瘤患者报告结局调查:用于鞍上脑膜瘤切除术的疾病特异性患者报告结局测量工具
研究对2013至2019年间接受经颅入路(TCA,n=14)或内镜经鼻入路(EEA,n=14)鞍上脑膜瘤切除术的成年患者进行半结构式访谈,通过扎根理论编码形成候选条目,并由32例患者和15名外科医生对条目相关性进行评分,最终构建包含25个条目的鞍上脑膜瘤患者报告结局调查(SMPRO)工具。
要点
- 定性分析产生55个候选条目,其中17个脑膜瘤特异性条目与8个PROMIS29条目共同构成25条目SMPRO。
- TCA患者较EEA患者报告术前未来展望更差(p=0.01)、术后2周药物所致疲倦(p=0.001)及术后3个月找词和记忆困难(p=0.05和<0.001)更显著。
- 外科医生整体高估了患者对问卷条目的关注程度(p<0.0005)。
核心结论
- 作者开发了针对鞍上脑膜瘤的疾病及入路特异性测量工具,用于按手术入路比较生活质量;若未来研究证实其信效度,该工具可能辅助患者和医生选择个体化手术入路。
研究设计与样本
- 对2013至2019年间接受鞍上脑膜瘤切除术的成年患者(EEA组n=14,TCA组n=14)进行半结构式访谈,采用扎根理论方法编码转录稿以识别主题。
- 32例患者和15名外科医生使用Likert量表对所得问卷及通用PROMIS29各条目的相关性进行评分,计算所有条目平均分并用非配对t检验比较TCA与EEA患者队列。
主要发现
- 定性分析产生55个候选条目。
- TCA患者较EEA患者报告术前未来展望更差(p=0.01)、术后2周药物所致疲倦(p=0.001)、术后3个月找词困难(p=0.05)和记忆困难(p<0.001)更显著。
- TCA患者最关注的条目包括术后药物所致嗜睡(2.9±1.3)、术前视物模糊(2.7±1.5)和术前因视物模糊阅读困难(2.7±2.7)。
- EEA患者最关注的条目包括术前视物模糊(3.5±1.3)、术前因视物模糊阅读困难(2.4±1.3)和术后嗅觉问题(2.9±1.3)。
- 外科医生整体高估患者对问卷条目的关注程度(p<0.0005),患者与外科医生相关性评分差异最大的条目为术前视物模糊(p<0.001)、术后视物模糊(p<0.001)和术后味觉问题(p<0.001)。
关键数值与推荐
- 患者对任一问卷条目平均评分≥2.0视为有意义,并汇总形成新型鞍上脑膜瘤患者报告结局调查(SMPRO)工具。
- 17个脑膜瘤特异性条目被认为有意义,补充8个有意义的PROMIS29条目,构成25条目的SMPRO。
临床怎么用
- 作者认为,若未来研究证实该工具可靠且有效,可能辅助患者和医生选择个体化手术入路。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Suprasellar meningioma resection via either the transcranial approach (TCA) or the endoscopic endonasal approach (EEA) is an area of controversy and active evaluation. Skull base surgeons increasingly consider patient-reported outcomes (PROs) when choosing an approach. No PRO measure currently exists to assess quality of life for suprasellar meningiomas. METHODS: Adult patients undergoing suprasellar meningioma resection between 2013 and 2019 via EEA (n = 14) or TCA (n = 14) underwent semistructured interviews. Transcripts were coded using a grounded theory approach to identify themes as the basis for a PRO measure that includes all uniquely reported symptoms. To assess content validity, 32 patients and 15 surgeons used a Likert scale to rate the relevance of items on the resulting questionnaire and the general Patient-Reported Outcomes Measurement Information System-29 (PROMIS29). The mean scores were calculated for all items and compared for TCA versus EEA patient cohorts by using unpaired t-tests. Items on either questionnaire with mean scores ≥ 2.0 from patients were considered meaningful and were aggregated to form the novel Suprasellar Meningioma Patient-Reported Outcome Survey (SMPRO) instrument. RESULTS: Qualitative analyses resulted in 55 candidate items. Relative to patients who underwent the EEA, those who underwent the TCA reported significantly worse future outlook before surgery (p = 0.01), tiredness from medications 2 weeks after surgery (p = 0.001), and word-finding and memory difficulties 3 months after surgery (p = 0.05 and < 0.001, respectively). The items that patients who received a TCA were most concerned about included medication-induced lethargy after surgery (2.9 ± 1.3), blurry vision before surgery (2.7 ± 1.5), and difficulty reading due to blurry vision before surgery (2.7 ± 2.7). Items that patients who received an EEA were most concerned about included blurry vision before surgery (3.5 ± 1.3), difficulty reading due to blurry vision before surgery (2.4 ± 1.3), and problems with smell postsurgery (2.9 ± 1.3). Although surgeons overall overestimated how concerned patients were about questionnaire items (p < 0.0005), the greatest discrepancies between patient and surgeon relevance scores were for blurry vision pre- and postoperatively (p < 0.001 and < 0.001, respectively) and problems with taste postoperatively (p < 0.001). Seventeen meningioma-specific items were considered meaningful, supplementing 8 significant PROMIS29 items to create the novel 25-item SMPRO. CONCLUSIONS: The authors developed a disease- and approach-specific measure for suprasellar meningiomas to compare quality of life by operative approach. If demonstrated to be reliable and valid in future studies, this instrument may assist patients and providers in choosing a personalized surgical approach.
引用
- Khalafallah AM, Rakovec M, Burapachaisri K, et al. The Suprasellar Meningioma Patient-Reported Outcome Survey: a disease-specific patient-reported outcome measure for resection of suprasellar meningioma. J Neurosurg. 2021. PMID: 34874673. doi:10.3171/2021.6.JNS21517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。